Yumanity Therapeutics, Inc. YMTX
We take great care to ensure that the data presented and summarized in this overview for YUMANITY THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding YMTX
View allLatest Institutional Activity in YMTX
Top Purchases
Top Sells
About YMTX
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Insider Transactions at YMTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2024
|
Raymond J. Bartoszek |
BUY
Other acquisition or disposition
|
Indirect |
903,995
+34.08%
|
$0
$0.55 P/Share
|
|
Dec 06
2023
|
Raymond J. Bartoszek |
BUY
Open market or private purchase
|
Direct |
250
+1.43%
|
$1,000
$4.5 P/Share
|
|
Dec 05
2023
|
Raymond J. Bartoszek |
BUY
Open market or private purchase
|
Direct |
1,000
+5.57%
|
$4,000
$4.5 P/Share
|
|
Dec 04
2023
|
Raymond J. Bartoszek |
BUY
Open market or private purchase
|
Direct |
1,000
+5.9%
|
$4,000
$4.33 P/Share
|
|
Nov 29
2023
|
Shawn Iadonato |
BUY
Open market or private purchase
|
Direct |
4,100
+0.6%
|
$12,300
$3.51 P/Share
|
|
Nov 28
2023
|
Craig W. Philips President and Secretary |
BUY
Open market or private purchase
|
Direct |
3,000
+4.7%
|
$9,000
$3.27 P/Share
|
|
Nov 28
2023
|
Shawn Iadonato |
BUY
Open market or private purchase
|
Direct |
900
+0.13%
|
$2,700
$3.33 P/Share
|
|
Oct 11
2023
|
Marion R Foote Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,443
+3.01%
|
$0
$0.14 P/Share
|
|
Sep 21
2023
|
Craig W. Philips President and Secretary |
BUY
Open market or private purchase
|
Direct |
2,900
+4.78%
|
$5,800
$2.4 P/Share
|
|
Sep 20
2023
|
Shawn Iadonato |
BUY
Open market or private purchase
|
Direct |
10,000
+1.47%
|
$20,000
$2.5 P/Share
|
|
Sep 20
2023
|
Pauline Kenny General Counsel & Secretary |
BUY
Open market or private purchase
|
Direct |
1,500
+7.52%
|
$3,000
$2.58 P/Share
|
|
Sep 20
2023
|
Craig W. Philips President and Secretary |
BUY
Open market or private purchase
|
Direct |
600
+1.08%
|
$1,200
$2.54 P/Share
|
|
Sep 19
2023
|
Raymond J. Bartoszek |
BUY
Open market or private purchase
|
Direct |
2,000
+11.8%
|
$4,000
$2.37 P/Share
|
|
Sep 18
2023
|
Raymond J. Bartoszek |
BUY
Open market or private purchase
|
Direct |
2,500
+16.17%
|
$5,000
$2.08 P/Share
|
|
Sep 18
2023
|
Keith Baker Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+22.85%
|
$10,000
$2.13 P/Share
|
|
Sep 15
2023
|
Raymond J. Bartoszek |
BUY
Open market or private purchase
|
Direct |
500
+4.56%
|
$1,000
$2.18 P/Share
|
|
Sep 14
2023
|
Thierry Guillaudeux Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+31.55%
|
$20,000
$2.0 P/Share
|
|
Jun 16
2023
|
Keith Baker Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+29.62%
|
$10,000
$2.92 P/Share
|
|
Jun 14
2023
|
Shawn Iadonato |
SELL
Payment of exercise price or tax liability
|
Direct |
7,439
-1.11%
|
$14,878
$2.82 P/Share
|
|
Jun 14
2023
|
Shawn Iadonato |
BUY
Exercise of conversion of derivative security
|
Direct |
1,382
+0.21%
|
$0
$0.14 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 67.2K shares |
|---|---|
| Open market or private purchase | 50.3K shares |
| Other acquisition or disposition | 904K shares |
| Payment of exercise price or tax liability | 21K shares |
|---|